Systemic sclerosis (SSc), or scleroderma, is a connective tissue disorder characterized by progressive fibrosis of the skin and internal organs. It has significance for gastroenterologists because the gastrointestinal tract is involved in 90% of SSc patients, who often present with esophageal dysfunction. Though the exact pathogenesis of SSc is unknown, there is increasing evidence supporting an immune mechanism. Cytokines are the soluble mediators of immune activation, altered fibroblast proliferation and extracellular matrix accumulation in SSc and thereby provide important therapeutic targets. In the present review, the involvement of cytokines in SSc is discussed with particular emphasis on cytokines and growth factors that have been implicated in the disease process and likely play an important role in the gastrointestinal manifestations of scleroderma. The role of cytokines as therapeutic targets in scleroderma forms the basis of this timely review.

**Key Words:** CTGF; Cytokines; GI dysfunction; IL-4; IL-6; MCP-1; PDGF; Scleroderma; TGF-β

**ORIGINAL ARTICLE**

Cytokines as therapeutic targets for the gastrointestinal manifestations of scleroderma

Jennifer M Raoul BSc1, Monica Verma MSc1, Ernest Tan BSc1, Theresa C Peterson PhD1,2

Cytokines : cible thérapeutique des manifestations gastro-intestinales de la sclérodermie

La sclérodermie, ou sclérose généralisée, est une maladie du tissu conjonctif, qui se caractérise par une fibre évolutive de la peau et des organes internes. L’affection revêt de l’importance pour les gastro-entérologues étant donné que le tube digestif est atteint dans 90 % des cas et que les troubles s’accompagnent d’un dysfonctionnement de l’œsophage. Même si on ne connaît pas précisément la pathogénie de la sclérodermie, de plus en plus de données permettent de croire à un mécanisme immunitaire. Les cytokines sont les médiateurs solubles de l’activation immunitaire, de la prolifération de fibroblastes anormaux et de l’accumulation de matrices extracellulaires observées dans la sclérodermie ; ces médiateurs constituent donc une cible thérapeutique toute désignée. Il sera question, dans le présent article, de la participation des cytokines dans la sclérodermie, plus particulièrement des cytokines et des facteurs de croissance mis en cause dans le processus morbide, qui jouent probablement un rôle important dans les manifestations gastro-intestinales de la sclérodermie. Le rôle des cytokines comme cible thérapeutique dans la sclérodermie constitue l’objet du présent examen.

Jennifer M Raoul BSc1, Monica Verma MSc1, Ernest Tan BSc1, Theresa C Peterson PhD1,2

**S**ystemic sclerosis (SSc), or scleroderma, is a connective tissue disorder characterized by progressive fibrosis of the skin and internal organs, as well as prominent changes in the microvasculature (1). There are two main subsets of the disease, referred to as limited and diffuse SSc. Diffuse SSc is the more serious form, because it affects visceral organs as well as the skin. SSc has considerable significance for gastroenterologists, because the gastrointestinal (GI) tract is the most commonly involved visceral system, and is affected in up to 90% of SSc patients (2). While esophageal dysfunction is the earliest and most prevalent GI manifestation, the disease has been shown to affect virtually all parts of the GI tract (2-4).

The disease is believed to progress in an organized fashion, beginning with a primary lesion of the autonomic nervous system before there is any physical damage to the smooth muscle (4). This often goes unnoticed by the patient. The initial neural insult is followed by smooth muscle atrophy, at which point GI symptoms generally become apparent. The final stage of the disease is the development of fibrosis leading to eventual loss of function (3). At this stage, the muscle is incapable of restoration and aggressive interventions may be required. Given the progressive fate of this disease, early diagnosis, accurate staging and appropriate treatment are important in delaying or preventing future complications. Unfortunately, GI involvement often goes unnoticed until complications have already arisen and, thus, the general therapeutic approach is to treat SSc manifestations as they arise (4). There are no effective treatments targeting the underlying disease process but understanding the factors that contribute to SSc pathology will enable the development of new therapies for this elusive and devastating disease.

**PATHOPHYSIOLOGY OF SSc**

The exact pathogenesis of SSc is unknown but there is increasing evidence supporting an immunologic theory, including T cell and B cell abnormalities (5). Antifibroblast autoantibodies have recently been identified that may promote activation of fibroblasts toward a proinflammatory/proadhesive phenotype, a key process in SSc pathology (6). Circulating autoantibodies have become useful markers of disease subset (7) and reports suggest that the diffuse and limited forms of the disease may be characterized by distinct cytokine and T cell profiles (8).

The pathophysiology of SSc includes at least three components: inappropriate immune activation; vascular damage and tissue atrophy; and the development of fibrosis (5,9). An activated immune system is the prominent feature of early disease, while propagation of the fibrotic phenotype prevails as the disease progresses (9). Disease stage and duration are important factors in determining appropriate therapeutic targets, with immunomodulation as the
immunosuppressive effects of TGF-β could be a useful target in SSc because inhibiting CTGF could be a downstream mediator of the profibrotic effects of TGF-β. CTGF is a mitogen for endothelial cells and fibroblasts, that is induced by TGF-β (11,12) and stimulates the production of ECM components including type I collagen (13). CTGF expression is significantly higher in skin fibroblasts, plasma and blister fluids from SSc patients compared with controls (24,25). Whereas TGF-β is detectable in certain prefibrotic lesions, CTGF is expressed in fibrotic SSc lesions (26) and correlates positively with the extent of fibrosis (27). Iloprost, a prostacyclin analogue with antifibrotic activity used in SSc patients, exerts its antifibrotic effects by inhibiting PDGF-induced expression of COL1A2 promoter (45). Treatment with a combination of iloprost and cyclosporin A for one year significantly decreased serum IL-6 levels and resulted in morphological and functional improvement in the esophagus, skin and microvasculature (46). Reduction of IL-6 and IL-4 decreased fibrosis in the TSK mouse model of SSc, resulting in marked reduction in skin thickness and serum levels of antinuclear antibodies (47), suggesting that IL-6 should be considered as part of an anticytokine approach to the treatment of SSc.

CTGF
CTGF is a mitogen for endothelial cells and fibroblasts, that is induced by TGF-β (11,12) and stimulates the production of ECM components including type I collagen (13). CTGF expression is significantly higher in skin fibroblasts, plasma and blister fluids from SSc patients compared with controls (24,25). Whereas TGF-β is detectable in certain prefibrotic lesions, CTGF is expressed in fibrotic SSc lesions (26) and correlates positively with the extent of fibrosis (27). Iloprost, a prostacyclin analogue with antifibrotic activity used in SSc patients, exerts its antifibrotic effects by inhibiting a specific cascade in the TGF-β signaling pathway, which abolishes CTGF-induction by TGF-β (28). CTGF is likely a downstream mediator of the profibrotic effects of TGF-β and could be a useful target in SSc because inhibiting CTGF could reduce fibrosis while sparing the beneficial antiproliferative and immunosuppressive effects of TGF-β.

PDGF
PDGF is a potent mitogen for fibroblasts and is implicated in the pathogenesis of SSc and other fibrotic diseases (10). PDGF stimulates proliferation of myofibroblasts in nonconfluent cultures, while stimulating collagen synthesis in confluent monolayers (29). Because fibroproliferation and collagen synthesis are two key processes in SSc pathology, PDGF is a potential therapeutic target in this disease. PDGF and its receptors are detectable in biopsy samples and skin from SSc patients, with highest levels in areas of active disease (10,30,31). PDGF acts synergistically with TGF-β in SSc fibroblasts and is known to induce the production of IL-6, another cytokine implicated in SSc pathology (32). Pentoxifylline (PTX) inhibited proliferation and collagen synthesis by cultured fibroblasts and myofibroblasts stimulated with PDGF (29,33) and cultured SSc fibroblasts (34). It also prevented the development of liver fibrosis in an experimental model (35). A recent study revealed that PTX interrupts PDGF-driven fibroproliferation by inhibiting PDGF-induced expression of c-jun (36). Antisense to c-jun also inhibited PDGF-induced fibroproliferation in this study. It was found that PTX specifically blocks the phosphorylation of c-Jun protein at serine residue 73. These findings suggest that pentoxifylline has considerable potential as an antifibrotic agent in SSc.

IL-4 AND IL-6
IL-4 is a profibrotic cytokine that has been implicated in SSc (37) and like PDGF, it also stimulates proliferation and collagen synthesis by fibroblasts (38). High serum levels of IL-4 correlate with increased disease severity in SSc patients (37) and in the tight-skin (TSK) mouse model of SSc (39). Fibroblasts from TSK mice show increased sensitivity to IL-4 and TGF-β and synthesize excessive amounts of collagen (40). Neutralizing antibodies against IL-4 were reported to reduce skin fibrosis in these mice (41) while mice deficient in IL-4 did not develop the fibrotic skin phenotype (42). Amelioration of dermal fibrosis by anti-IL-4 treatment in TSK mice suggests that IL-4 is a contributing factor, but reports that transgenic mice overexpressing IL-4 do not develop SSc symptoms (43) indicate that IL-4 is not a causal agent in SSc.

IL-6 levels are elevated in serum from SSc patients and correlate positively with skin thickness, making it a useful serological indicator of skin fibrosis (44). IL-6 production by SSc fibroblasts is significantly increased (30-fold) compared with normal fibroblasts and may be the result of constitutive binding of nuclear factors to the IL-6 promoter (45). Treatment with a combination of iloprost and cyclosporin A for one year significantly decreased serum IL-6 levels and resulted in morphological and functional improvement in the esophagus, skin and microvasculature (46). Reduction of IL-6 and IL-4 decreased fibrosis in the TSK mouse model of SSc, resulting in marked reduction in skin thickness and serum levels of antinuclear antibodies (47), suggesting that IL-6 should be considered as part of an anticytokine approach to the treatment of SSc.

MCP-1
MCP-1 is a chemokine involved in recruiting and activating immune cells during inflammation (48) and is expressed in SSc skin lesions by fibroblasts and infiltrating mononuclear cells (49). MCP-1 was elevated in serum from SSc patients where it correlated with the presence of pulmonary fibrosis (50). The increased expression of MCP-1 by SSc fibroblasts is thought to contribute to the presence of perivascular infiltrates of inflammatory cells in SSc patients, implicating a role in early processes leading to SSc lesions (51). This was supported in an experimental model of SSc, where MCP-1 was expressed before the development of any skin or lung fibrosis (52). Therapeutic strategies targeting MCP-1 may have beneficial effects in SSc, particularly in the early stages of disease development.

Can J Gastroenterol Vol 18 No 1 January 2004
REFERENCES


